
Camlin Fine Q3 FY24 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 2
Margin
Category 3
Fundraise
N/A
Order
N/A
Capex
Yes
1 of 3 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 2- Vanillin sales provide significant growth potential as current sales are insignificant; expected scale-up to contribute substantially to revenue (Page 9).
- Vanillin utilization expected to reach 40-50% in FY25, with potential for higher utilization if market conditions improve (Pages 14, 7).
- New product introductions underway with aggressive rollout planned in FY25; new products expected to contribute about 10% of business next year (Page 13).
- Blends business in North America, Mexico, and Brazil growing well with sustainable margins; expected to maintain profitability and grow ~25% in FY25 (Pages 8, 9).
- Indian facility running at ~90% utilization; growth expected from volume scale-up rather than pricing alone (Page 9).
- Price pressures from Chinese dumping expected to ease in 2-3 quarters, potentially aiding volume and revenue growth (Pages 9, 11).
- European plant revenue anticipated to rise post-Q4 FY24 with ongoing cost control measures (Pages 7, 14).
See what Camlin Fine management said on margin guidance — free account, 30 seconds.
Fundraise plans
See what Camlin Fine management said on order book — free account, 30 seconds.
Capex plans
Yes- The company is exploring an increase in capacity for Lockheed Martin orders after fulfilling the initial supply by March 2024; more clarity expected in the next quarter.
- CFS Europe plant is contemplating alternative uses, including manufacturing another HQ downstream product by a different chemistry, with a course of action to be finalized by March 2024.
- The Chinese subsidiary plant remains closed but is planned to be restarted in the second half of FY25, focusing on manufacturing Heliotropin (catechol downstream).
- No explicit mention of new major capex projects; emphasis is on optimizing existing capacities, reducing fixed costs, and scaling up Vanillin plant utilization progressively (expected 40-50% utilization in FY25).
- The company is calibrating vanillin production based on market conditions, gradually shifting production focus (from ethyl vanillin to methyl vanillin).
- Overall, focus appears on strategic capacity utilization improvements rather than large new capital investments at present.
Track Camlin Fine — get its next earnings analysis in your feed
How does Camlin Fine rank vs peers in Chemicals & Petrochemicals?
Pro featureHow does Camlin Fine rank in Chemicals & Petrochemicals?
Compare Camlin Fine against every Chemicals & Petrochemicals company (Q3 FY24) on revenue, margins and earnings-call signals.
Continue your research
What Camlin Fine's management said in earlier quarters
Others in Chemicals & Petrochemicals this season
- Seya Industries (Q2 FY27)
Revenue from Operations (Net) for the quarter ended September 30, 2026: ₹0 lakhs (no sales reported). Key results statement takeaways from Seya Industries Ltd's
- DCM Shriram Fine Chemicals (Q2 FY27)
9,622.39 lakhs for the quarter ended September 30, 2025, indicating a year-on-year decrease of approximately 7.8%. Key results statement takeaways from DCM Shri
- Dhariwalcorp (Q2 FY27)
For the half year ended September 30, 2026, consolidated revenue from operations is ₹23,640.36 lakhs, up from ₹17,767.97 lakhs in the previous comparable…
- Agastya Energy (Q2 FY27)
For the quarter ended 30th September 2026, the consolidated revenue from operations was ₹625.15 lakhs, down from ₹4410.2 lakhs in the same quarter last year…